8-K current report · filed Oct 27, 2026

Atrium Therapeutics, Inc. (RNA) 8-K Current Report: October 27, 2026

Item 8.01Item EX-99.1RNA overview

Short answer

Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). First patient dosed in Phase 1/2 Corventis trial of ATR 1072 for PRKAG2 syndrome.

Atrium Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • First patient dosed in Phase 1/2 Corventis trial of ATR 1072 for PRKAG2 syndrome
  • Clinical-stage milestone advances lead program into human testing
  • Trial progress creates potential catalyst, while efficacy and safety remain unproven
  • Press release details available in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • First patient dosed in Corventis, a Phase 1/2 trial testing ATR 1072 for PRKAG2 syndrome
  • Approximately 37 participants planned across dose-escalation and expansion cohorts
  • Initial proof-of-concept data expected in the second half of 2027, creating a major clinical catalyst
  • No approved therapies exist for PRKAG2 syndrome, supporting significant unmet-need positioning
  • Key risks: rare-disease enrollment, safety findings, and unproven ability of ATR 1072 to improve cardiac function

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Atrium Therapeutics, Inc. 8-K filings

Get the next RNA 8-K as it lands

Follow RNA for push alerts, or ask the research agent what this filing means.